January 31, 2013 / 10:50 AM / 4 years ago

EU regulators charge J&J, Novartis over Dutch painkiller delay

1 Min Read

BRUSSELS, Jan 31 (Reuters) - EU antitrust regulators charged pharmaceutical firms Johnson & Johnson and Novartis on Thursday over the delay of a generic competitor for painkiller fentanyl in the Dutch market.

The European Commission, which acts as antitrust regulator in the 27-nation European Union, said it had sent a "statement of objections" or charge sheet to the companies over an agreement between their Dutch subsidiaries.

"If our preliminary conclusions are confirmed, the Dutch subsidiaries of Johnson & Johnson and Novartis entered into a so-called 'co-promotion' agreement to avoid competing against each other, depriving users of fentanyl in the Netherlands from access to a cheaper painkiller," the Commission said in a statement.

The charges arose from an investigation of the pharmaceuticals sector after a Commission report highlighted deals between major drugmakers aimed at hindering or blocking generic medicines in "pay-for-delay" deals.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below